Cargando…
Checkpoint inhibitors and radiotherapy in refractory malignant melanocytic schwannoma with Carney complex: first evidence of efficacy
Melanocytic schwannoma (MS) is a rare nerve sheath tumour characterised by melanin-producing neoplastic schwann cells that typically affects the posterior spinal nerve roots. We report an ultrarare case of recurrent/metastatic MS associated with Carney complex in a young woman with family history of...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166596/ https://www.ncbi.nlm.nih.gov/pubmed/34049890 http://dx.doi.org/10.1136/bcr-2020-240296 |
_version_ | 1783701529324158976 |
---|---|
author | Bajpai, Jyoti Kapoor, Akhil Jalali, Rakesh Gounder, Mrinal M |
author_facet | Bajpai, Jyoti Kapoor, Akhil Jalali, Rakesh Gounder, Mrinal M |
author_sort | Bajpai, Jyoti |
collection | PubMed |
description | Melanocytic schwannoma (MS) is a rare nerve sheath tumour characterised by melanin-producing neoplastic schwann cells that typically affects the posterior spinal nerve roots. We report an ultrarare case of recurrent/metastatic MS associated with Carney complex in a young woman with family history of breast cancer. This highlights the novel approach of combined checkpoint inhibitors (CPI) and radiotherapy. The patient was initially treated with Nivolumab along with concurrent external beam radiotherapy. There was sustained clinical benefit achieved for over 15 months with preserved quality of life. Addition of Ipilimumab, which she tolerated reasonably well, helped to control the progressive disease again for another 12 months. She harboured a rare PRKAR1A R228 mutation (Carney complex) and received appropriate targeted therapy. She survived for 51 and 35 months from her initial diagnosis and start of CPI, respectively, which to the best of our knowledge is the longest documented survival in this rare entity. |
format | Online Article Text |
id | pubmed-8166596 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-81665962021-06-14 Checkpoint inhibitors and radiotherapy in refractory malignant melanocytic schwannoma with Carney complex: first evidence of efficacy Bajpai, Jyoti Kapoor, Akhil Jalali, Rakesh Gounder, Mrinal M BMJ Case Rep Case Report Melanocytic schwannoma (MS) is a rare nerve sheath tumour characterised by melanin-producing neoplastic schwann cells that typically affects the posterior spinal nerve roots. We report an ultrarare case of recurrent/metastatic MS associated with Carney complex in a young woman with family history of breast cancer. This highlights the novel approach of combined checkpoint inhibitors (CPI) and radiotherapy. The patient was initially treated with Nivolumab along with concurrent external beam radiotherapy. There was sustained clinical benefit achieved for over 15 months with preserved quality of life. Addition of Ipilimumab, which she tolerated reasonably well, helped to control the progressive disease again for another 12 months. She harboured a rare PRKAR1A R228 mutation (Carney complex) and received appropriate targeted therapy. She survived for 51 and 35 months from her initial diagnosis and start of CPI, respectively, which to the best of our knowledge is the longest documented survival in this rare entity. BMJ Publishing Group 2021-05-28 /pmc/articles/PMC8166596/ /pubmed/34049890 http://dx.doi.org/10.1136/bcr-2020-240296 Text en © BMJ Publishing Group Limited 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Case Report Bajpai, Jyoti Kapoor, Akhil Jalali, Rakesh Gounder, Mrinal M Checkpoint inhibitors and radiotherapy in refractory malignant melanocytic schwannoma with Carney complex: first evidence of efficacy |
title | Checkpoint inhibitors and radiotherapy in refractory malignant melanocytic schwannoma with Carney complex: first evidence of efficacy |
title_full | Checkpoint inhibitors and radiotherapy in refractory malignant melanocytic schwannoma with Carney complex: first evidence of efficacy |
title_fullStr | Checkpoint inhibitors and radiotherapy in refractory malignant melanocytic schwannoma with Carney complex: first evidence of efficacy |
title_full_unstemmed | Checkpoint inhibitors and radiotherapy in refractory malignant melanocytic schwannoma with Carney complex: first evidence of efficacy |
title_short | Checkpoint inhibitors and radiotherapy in refractory malignant melanocytic schwannoma with Carney complex: first evidence of efficacy |
title_sort | checkpoint inhibitors and radiotherapy in refractory malignant melanocytic schwannoma with carney complex: first evidence of efficacy |
topic | Case Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8166596/ https://www.ncbi.nlm.nih.gov/pubmed/34049890 http://dx.doi.org/10.1136/bcr-2020-240296 |
work_keys_str_mv | AT bajpaijyoti checkpointinhibitorsandradiotherapyinrefractorymalignantmelanocyticschwannomawithcarneycomplexfirstevidenceofefficacy AT kapoorakhil checkpointinhibitorsandradiotherapyinrefractorymalignantmelanocyticschwannomawithcarneycomplexfirstevidenceofefficacy AT jalalirakesh checkpointinhibitorsandradiotherapyinrefractorymalignantmelanocyticschwannomawithcarneycomplexfirstevidenceofefficacy AT goundermrinalm checkpointinhibitorsandradiotherapyinrefractorymalignantmelanocyticschwannomawithcarneycomplexfirstevidenceofefficacy |